Please provide your email address to receive an email when new articles are posted on . MILAN — In this video perspective at the ESCRS meeting, Dominique Brémond-Gignac, MD, PhD, speaks about ...

Please provide your email address to receive an email when new articles are posted on . In June 2021, Verkazia was approved for the treatment of vernal keratoconjunctivitis in children and adults. OSN ...

The approval was based on data from two randomized, multicenter, double-masked, vehicle-controlled trials that evaluated the efficacy and safety of Verkazia in patients with VKC. The Food and Drug ...

Invirsa has also received approval from the FDA equivalent authority in Thailand to proceed with Phase 2 Acute Infectious Keratoconjunctivitis clinical trial in Bangkok COLUMBUS, Ohio--(BUSINESS WIRE) ...

(MENAFN- EIN Presswire) EINPresswire/ -- Neurotrophic Keratitis Treatment Market to Surpass $5 billion in 2029. In comparison, the Central Nervous System Drugs market, which is considered as its ...

Vernal keratoconjunctivitis (VKC) is a chronic, bilateral, allergic condition primarily affecting children and young adults. It is a seasonal allergic inflammatory disease of the eye with episodes of ...

‒ Phase 4 open-label study showed clinically important improvement in the patient-reported Impact of Dry Eye on Everyday Life (IDEEL) symptom bother score, the study's primary outcome measure - DUBLIN ...

Corneal disease is the primary cause of visual loss in allergic eye disease. It occurs almost exclusively in vernal keratoconjunctivitis and atopic keratoconjunctivitis. It is characterized by ...

(MENAFN- GetNews) The present Vernal keratoconjunctivitis market size in all the markets of interest was estimated to be USD 307.89 million in 2017 and is anticipated to increase further by 2030 owing ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...